Writing on product systems, fintech infrastructure, market behavior, and leadership lessons from practical execution.
📚 Books
Beyond platform leadership and infrastructure design, I write about trading psychology, financial literacy, and structured market participation.
Both books are published globally on Amazon (Kindle & Paperback editions available).
🟦 The Mind Game of Trading
Mastering Psychology for Consistent Profits
By Sreenivasulu Malkari
Overview
Trading success is rarely limited by strategy. It is limited by psychology.
In The Mind Game of Trading, I distill 15+ years of real-world trading experience into a structured framework for mastering discipline, emotional control, and execution integrity.
The book focuses on:
• Identifying hidden cognitive biases
• Structured journaling & checklist systems
• Emotional risk management
• Practical trading plan templates
• Long-term consistency frameworks
This is not a theory book — it is a practical discipline manual for traders at all levels.
🔗 Available on Amazon (Paperback & Kindle)
👉 https://www.amazon.com/dp/B0FNKGB7W2
🟦 The Stock Market Starter Kit
Learn to Trade Smart in 7 Days
By Sreenivasulu Malkari
Overview
Designed for beginners entering the Indian stock market, this book simplifies complex concepts into a structured 7-day learning framework.
It emphasizes structured thinking, capital protection, and long-term consistency as the core pillars of intelligent market participation.
It covers:
• How stock markets function (NSE/BSE context)
• Intraday, swing & long-term trading basics
• Risk management principles
• Chart reading fundamentals
• Practical checklists and action plans
Clear. Structured. Actionable.
🔗 Available on Amazon (Paperback & Kindle)
👉 https://www.amazon.com/dp/B0FF2NK8MV
-
Tata Motors Share Price Falls as JPMorgan Cuts Target Price: What Indian Investors Should Know
Tata Motors Share Price Declines: JPMorgan Slashes Target Price Tata Motors share price declined 0.33% on Friday at intraday after JPMorgan reduced the target price for the scrip from Rs 700 to Rs 385. The brokerage has a cautious view on JLR, which drives a Neutral rating on the stock, JPMorgan said. This move has…
-
Indian Oil Corporation Q2 Results: What to Expect and How to React
Indian Oil Corporation Q2 Results: An Overview Indian Oil Corporation Ltd. (IOCL) is one of the most important oil and gas companies in India, serving around 3.2 crore customers daily. The company is set to announce its results for the quarter and half-year ended September 30, next week. In this article, we will discuss everything…
-
HUL Share Price Falls 4% After Q2 Results: What Do Analysts Say?
HUL Share Price Falls 4% After Q2 Results: What Do Analysts Say? Hindustan Unilever Ltd. shares declined as much as nearly 5% during trade so far, after the company posted its second quarter results early Thursday. The decline in share price came despite a largely positive consensus among top brokerages, who have maintained their ‘buy’…
-
Orkla India IPO: MTR Foods Parent Sets Price Band at Rs 695-730 per Share
Orkla India IPO: A New Opportunity for Investors Orkla India Ltd., the owner of popular spices and condiments brands MTR and Eastern, has announced the price band for its upcoming initial public offering (IPO). The IPO will open for subscription on October 29 and close on October 31, with investors able to bid in the…
-
Q2 Earnings Today: Coforge, SBI Life, SBI Cards, Dr. Reddy’s Laboratories Results Preview
Q2 Earnings Today: Top Companies to Watch Dr. Reddy’s Laboratories Ltd., Coforge Ltd., SBI Life Insurance Company Ltd., and SBI Cards and Payments Services Ltd. are among the top names that will announce their quarterly results on Friday. In this article, we will delve into the earnings estimates of these companies and provide insights into…
-
Laurus Labs Q2 Results: Decoding the Surge in Net Profit and Its Impact on Investors
Laurus Labs Q2 Results: A Comprehensive Analysis Laurus Labs Ltd. shares declined over 3% on Friday, a day after the company reported strong second-quarter earnings. The decline comes despite the pharmaceutical firm posting a robust performance for the July–September period, with consolidated revenue rising 35.1% year-on-year to Rs 1,653.47 crore and net profit surging 883%…